Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study. Issue 11 (November 2017)
- Record Type:
- Journal Article
- Title:
- Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study. Issue 11 (November 2017)
- Main Title:
- Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study
- Authors:
- Verguet, Stéphane
Riumallo-Herl, Carlos
Gomez, Gabriela B
Menzies, Nicolas A
Houben, Rein M G J
Sumner, Tom
Lalli, Marek
White, Richard G
Salomon, Joshua A
Cohen, Ted
Foster, Nicola
Chatterjee, Susmita
Sweeney, Sedona
Baena, Inés Garcia
Lönnroth, Knut
Weil, Diana E
Vassall, Anna - Abstract:
- Summary: Background: The economic burden on households affected by tuberculosis through costs to patients can be catastrophic. WHO's End TB Strategy recognises and aims to eliminate these potentially devastating economic effects. We assessed whether aggressive expansion of tuberculosis services might reduce catastrophic costs. Methods: We estimated the reduction in tuberculosis-related catastrophic costs with an aggressive expansion of tuberculosis services in India and South Africa from 2016 to 2035, in line with the End TB Strategy. Using modelled incidence and mortality for tuberculosis and patient-incurred cost estimates, we investigated three intervention scenarios: improved treatment of drug-sensitive tuberculosis; improved treatment of multidrug-resistant tuberculosis; and expansion of access to tuberculosis care through intensified case finding (South Africa only). We defined tuberculosis-related catastrophic costs as the sum of direct medical, direct non-medical, and indirect costs to patients exceeding 20% of total annual household income. Intervention effects were quantified as changes in the number of households incurring catastrophic costs and were assessed by quintiles of household income. Findings: In India and South Africa, improvements in treatment for drug-sensitive and multidrug-resistant tuberculosis could reduce the number of households incurring tuberculosis-related catastrophic costs by 6–19%. The benefits would be greatest for the poorest households.Summary: Background: The economic burden on households affected by tuberculosis through costs to patients can be catastrophic. WHO's End TB Strategy recognises and aims to eliminate these potentially devastating economic effects. We assessed whether aggressive expansion of tuberculosis services might reduce catastrophic costs. Methods: We estimated the reduction in tuberculosis-related catastrophic costs with an aggressive expansion of tuberculosis services in India and South Africa from 2016 to 2035, in line with the End TB Strategy. Using modelled incidence and mortality for tuberculosis and patient-incurred cost estimates, we investigated three intervention scenarios: improved treatment of drug-sensitive tuberculosis; improved treatment of multidrug-resistant tuberculosis; and expansion of access to tuberculosis care through intensified case finding (South Africa only). We defined tuberculosis-related catastrophic costs as the sum of direct medical, direct non-medical, and indirect costs to patients exceeding 20% of total annual household income. Intervention effects were quantified as changes in the number of households incurring catastrophic costs and were assessed by quintiles of household income. Findings: In India and South Africa, improvements in treatment for drug-sensitive and multidrug-resistant tuberculosis could reduce the number of households incurring tuberculosis-related catastrophic costs by 6–19%. The benefits would be greatest for the poorest households. In South Africa, expanded access to care could decrease household tuberculosis-related catastrophic costs by 5–20%, but gains would be seen largely after 5–10 years. Interpretation: Aggressive expansion of tuberculosis services in India and South Africa could lessen, although not eliminate, the catastrophic financial burden on affected households. Funding: Bill & Melinda Gates Foundation. … (more)
- Is Part Of:
- Lancet. Volume 5:Issue 11(2017)
- Journal:
- Lancet
- Issue:
- Volume 5:Issue 11(2017)
- Issue Display:
- Volume 5, Issue 11 (2017)
- Year:
- 2017
- Volume:
- 5
- Issue:
- 11
- Issue Sort Value:
- 2017-0005-0011-0000
- Page Start:
- e1123
- Page End:
- e1132
- Publication Date:
- 2017-11
- Subjects:
- World health -- Periodicals
362.105 - Journal URLs:
- http://www.sciencedirect.com/science/journal/2214109X ↗
http://www.sciencedirect.com/ ↗ - DOI:
- 10.1016/S2214-109X(17)30341-8 ↗
- Languages:
- English
- ISSNs:
- 2214-109X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 4746.xml